The Wistar Institute is pleased to welcome Aleister Saunders, Ph.D., and Patrick Oates, Ph.D., to its Board of Trustees. The two new trustees bring a wealth of experience in biomedical research, technology transfer, and drug development to Wistar’s mission.
Wistar researchers successfully tested a simple intervention that could unlock greater anti-tumor power in therapies that use T cells — an approach known as “cell-based therapy,” which uses specially designed T cells to fight cancer.
Dario C. Altieri, M.D. — The Wistar Institute’s president and CEO, director of its Ellen and Ronald Caplan Cancer Center and the Robert & Penny Fox Distinguished Professor — is a recipient of the 2023 Most Admired CEO Awards recognized by the Philadelphia Business Journal for his leadership and service to Wistar.
The Wistar Institute announces the appointment of Dean Stoios as Chief Financial Officer.
Dario C. Altieri, M.D., Wistar president and CEO, will be honored by the Justinian Foundation and Society of Philadelphia for exemplifying the finest qualities of scholarship, civic leadership and integrity.
Zachary Schug, Ph.D., assistant professor at The Wistar Institute, has published a new paper in the journal Nature Cancer demonstrating a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
Wistar is pleased to announce the recruitment of Avi Srivastava, Ph.D., to the Ellen and Ronald Caplan Cancer Center, where he joins Wistar’s Gene Expression and Regulation Program as an Assistant Professor.
Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio.
The Wistar Institute is pleased to announce the appointment of Alexander Price, Ph.D., as assistant professor in the Gene Expression and Regulation Program of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute.
The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Joy Taylor to its Board of Trustees. Taylor is CEO of EastEdge Consulting Services, a Pennsylvania-based management consulting firm focused on organizational and operational improvement.
Scientists have long used community advisory boards to engage communities and provide feedback on studies, but this model has limitations. Now, Wistar Institute researchers are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.
Wistar hosts its 27th Jonathan Lax Memorial Lecture Thursday, June 29th at 5:30 pm EST.
PHILADELPHIA — (June 20, 2023) — When cancer that starts in the body metastasizes to the brain, it is almost always lethal, in part because so few treatment options exist. Now a new study by Wistar scientists published in Nature Communications shows that a type of brain cell called astrocytes plays an important role in promoting brain metastasis by recruiting a specific subpopulation of immune cells.
Wistar is pleased to welcome Sozi Tulante to its Board of Trustees. He is currently General Counsel of Form Energy, a Massachusetts-based energy storage technology and manufacturing company.
Wistar Institute has formed a collaboration with the Pennsylvania Biotechnology Center and the Baruch S. Blumberg Institute to accelerate the advancement of “bench to bedside” biomedical research discoveries in the tri-state region.
Wistar Institute researchers have uncovered a key mechanism as to how p53 suppresses tumors.
Wistar Institute researchers identified hopeaphenol, a natural plant-based compound, as possessing antiviral properties that are effective against HIV.
Wistar scientists have identified a gene signature that accurately predicts the functioning of P53 variants, important information to assessing cancer risk and optimizing choices for cancer therapeutics.
The Cotswold Foundation Postdoctoral Fellowship is a new fellowship totaling $500,000 over the course of five years to support a postdoctoral researcher studying immunology, cancer research, or vaccine biology at The Wistar Institute.
The Wistar Institute, which has recently launched a $75 million programmatic campaign investing in biomedical advances, announces the appointment of Michael Criscuolo as Vice President of Development.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right